内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NKTR 内克塔治疗

盘后交易 02-04 16:33:54 EST

37.64

-1.21

-3.13%

盘后37.08

-0.56-1.49%

16:23 EST

最高38.93	最低36.13	成交量58.74万
今开38.44	昨收38.86	日振幅7.21%
总市值7.66亿	流通市值6.62亿	总股本2,034万
成交额2,183万	换手率3.34%	流通股本1,759万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":37.64,"timestamp":1770238800000,"preClose":38.855,"halted":0,"volume":587388,"hourTrading":{"tag":"盘后","latestPrice":37.08,"preClose":37.64,"latestTime":"16:23 EST","volume":5701,"amount":214563.23506999997,"timestamp":1770240200014,"change":-0.56,"changeRate":-0.014878,"amplitude":0.014878},"delay":0,"changeRate":-0.03127010680736061,"floatShares":17594200,"shares":20341589,"eps":-7.899717,"marketStatus":"盘后交易","change":-1.215,"latestTime":"02-04 16:33:54 EST","open":38.44,"high":38.93,"low":36.13,"amount":21828407.12616,"amplitude":0.072063,"askPrice":38.37,"askSize":52,"bidPrice":36.91,"bidSize":54,"shortable":3,"etf":0,"ttmEps":-7.899717,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770253200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":38.855,"preHourTrading":{"tag":"盘前","latestPrice":39.2238,"preClose":38.855,"latestTime":"09:22 EST","volume":15,"amount":577.21899,"timestamp":1770214948455,"change":0.3688,"changeRate":0.009492,"amplitude":0.028666},"postHourTrading":{"tag":"盘后","latestPrice":37.08,"preClose":37.64,"latestTime":"16:23 EST","volume":5701,"amount":214563.23506999997,"timestamp":1770240200014,"change":-0.56,"changeRate":-0.014878,"amplitude":0.014878},"volumeRatio":0.866805,"impliedVol":1.1609,"impliedVolPercentile":0.58},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2603363905","title":"内克塔治疗盘中异动 急速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603363905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603363905?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:13","pubTimestamp":1768317226,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日23时13分，内克塔治疗股票出现异动，股价大幅下跌5.00%。截至发稿，该股报36.83美元/股，成交量16.183万股，换手率0.80%，振幅5.08%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.42%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323134697a1a918&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011323134697a1a918&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2602349969","title":"内克塔治疗盘中异动 临近收盘急速下跌5.19%报41.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602349969?lang=zh_cn&edition=full","pubTime":"2026-01-09 04:37","pubTimestamp":1767904648,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时37分，内克塔治疗股票出现异动，股价大幅下跌5.19%。截至发稿，该股报41.25美元/股，成交量37.2958万股，换手率1.83%，振幅5.61%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.90%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2595117357","title":"内克塔治疗盘中异动 大幅下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595117357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595117357?lang=zh_cn&edition=full","pubTime":"2025-12-30 03:46","pubTimestamp":1767037570,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日03时46分，内克塔治疗股票出现异动，股价急速下挫5.03%。截至发稿，该股报42.25美元/股，成交量46.1589万股，换手率2.27%，振幅4.65%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.64%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1111891041","title":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1111891041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111891041?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:45","pubTimestamp":1765892748,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1180977691","title":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1180977691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180977691?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:16","pubTimestamp":1765890968,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1190845593","title":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1190845593","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190845593?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890469,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1101661185","title":"内克塔治疗 - Rezolve-Aa II期B研究达成目标产品特征，盐分评分降低28.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101661185","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101661185?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890441,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa II期B研究达成了目标产品特征，盐分评分降低了28.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1125532009","title":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125532009","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125532009?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:00","pubTimestamp":1765839610,"startTime":"0","endTime":"0","summary":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1173506245","title":"Nektar Therapeutics第三季度每股收益为-1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173506245","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173506245?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:04","pubTimestamp":1763571844,"startTime":"0","endTime":"0","summary":"11月6日 - 内克塔治疗第三季度的运营收入为-316,720,000美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2583275656","title":"内克塔治疗2025财年第三财季实现净利润-35.52百万美元，同比增加4.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583275656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583275656?lang=zh_cn&edition=full","pubTime":"2025-11-16 00:02","pubTimestamp":1763222561,"startTime":"0","endTime":"0","summary":"11月16日，内克塔治疗公布财报，公告显示公司2025财年第三财季净利润为-35.52百万美元，同比增加4.16%；其中营业收入为11.79百万美元，同比减少51.12%，每股基本收益为-1.87美元。从资产负债表来看，内克塔治疗总负债2.16亿美元，其中短期债务22.18百万美元，资产负债比为1.40，流动比率为0.05。机构评级：截至2025年11月16日，当前有7家机构对内克塔治疗目标价做出预测，其中目标均价为93.86美元，其中最低目标价为30.00美元，最高目标价为120.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111600033095068119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111600033095068119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR"],"gpt_icon":0},{"id":"2583226656","title":"内克塔治疗盘中异动 急速拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583226656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583226656?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:10","pubTimestamp":1763147426,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日03时10分，内克塔治疗股票出现波动，股价大幅上涨5.21%。截至发稿，该股报56.76美元/股，成交量35.4551万股，换手率1.74%，振幅7.41%。机构评级方面，在所有9家参与评级的机构中，78%的券商给予买入建议，11%的券商给予持有建议，11%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.90%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115031027a4a239c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115031027a4a239c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1194489688","title":"内克塔治疗宣布Rezpegaldesleukin的Rezolve-Ad 2B期试验结果入选2025年欧洲皮肤病与性病学会年会重磅口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1194489688","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194489688?lang=zh_cn&edition=full","pubTime":"2025-09-09 19:01","pubTimestamp":1757415708,"startTime":"0","endTime":"0","summary":"内克塔治疗宣布Rezpegaldesleukin的Rezolve-Ad 2B期试验结果入选2025年欧洲皮肤病与性病学会年会重磅口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2561483893","title":"内克塔治疗盘中异动 股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561483893","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561483893?lang=zh_cn&edition=full","pubTime":"2025-08-20 22:17","pubTimestamp":1755699448,"startTime":"0","endTime":"0","summary":"北京时间2025年08月20日22时17分，内克塔治疗股票出现波动，股价急速下挫5.12%。截至发稿，该股报25.35美元/股，成交量9.5023万股，换手率0.50%，振幅5.46%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.57%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820221728a6f16568&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820221728a6f16568&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2557957859","title":"内克塔治疗盘中异动 早盘大幅拉升7.40%报23.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557957859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557957859?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:32","pubTimestamp":1754659946,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时32分，内克塔治疗股票出现波动，股价急速拉升7.40%。截至发稿，该股报23.36美元/股，成交量2.0432万股，换手率0.12%，振幅2.07%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.08%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213226a6db2070&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213226a6db2070&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2518278576","title":"内克塔治疗盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278576?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613473,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，内克塔治疗股票出现异动，股价急速下跌5.25%。截至发稿，该股报0.832美元/股，成交量8612股，换手率0.00%，振幅0.00%。机构评级方面，在所有9家参与评级的机构中，44%的券商给予买入建议，44%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.59%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2517416256","title":"内克塔治疗盘中异动 股价大涨5.06%报0.901美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517416256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517416256?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276885,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时01分，内克塔治疗股票出现波动，股价快速上涨5.06%。截至发稿，该股报0.901美元/股，成交量26.0674万股，换手率0.14%，振幅9.76%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.47%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2517602474","title":"内克塔治疗盘中异动 股价大涨5.45%报0.846美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517602474?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:59","pubTimestamp":1741111142,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时59分，内克塔治疗股票出现异动，股价急速上涨5.45%。截至发稿，该股报0.846美元/股，成交量79.266万股，换手率0.43%，振幅8.90%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.35%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2516744543","title":"内克塔治疗盘中异动 快速拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516744543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516744543?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:53","pubTimestamp":1740761596,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时53分，内克塔治疗股票出现异动，股价大幅上涨5.15%。截至发稿，该股报0.837美元/股，成交量36.4781万股，换手率0.20%，振幅7.33%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.47%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2514385612","title":"内克塔治疗盘中异动 急速上涨6.36%报0.830美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385612?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666680,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，内克塔治疗股票出现波动，股价快速拉升6.36%。截至发稿，该股报0.830美元/股，成交量2.2083万股，换手率0.01%，振幅7.64%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.06%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2514522098","title":"内克塔治疗盘中异动 早盘股价大跌5.00%报0.827美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514522098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514522098?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:59","pubTimestamp":1740585583,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时59分，内克塔治疗股票出现异动，股价大幅下挫5.00%。截至发稿，该股报0.827美元/股，成交量84.9661万股，换手率0.46%，振幅9.99%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.07%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235943a2550bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235943a2550bd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":-0.1051},{"period":"3month","weight":-0.2839},{"period":"6month","weight":0.7864},{"period":"1year","weight":2.2023},{"period":"ytd","weight":-0.081}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立，并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司，专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内，该公司致力于创造新的免疫调节剂，选择性地诱导、放大、减弱或阻止免疫反应，以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.004269},{"month":3,"riseRate":0.387097,"avgChangeRate":-0.002052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}